Articles related to FDA

Explore the latest breakthrough in GAD treatment: MM120 demonstrates remarkable, sustained reduction in anxiety symptoms, offering new hope for patients with severe generalized anxiety disorder.

In oncology, the balance between rapid innovation and patient safety is critical. The recent withdrawal of an accelerated approval cancer drug highlights the need for more stringent evidence and robust trial design to truly benefit patients.

Explore the latest advancement in NSCLC treatment: the FDA-approved amivantamab combo has demonstrated a significant leap in progression-free survival for patients with specific genetic mutations, reshaping the standard of care.

Explore the recent FDA approval of biweekly teclistamab dosing for multiple myeloma, a significant stride in offering personalized treatment schedules that cater to patient and clinician needs.

Amtagvi’s approval introduces a novel approach in the treatment of advanced melanoma, employing patient-derived TIL-cell therapy to target tumors with precision, offering a beacon of hope for those with limited options.

Better Therapeutics’ digital therapeutic app has been recognized with FDA breakthrough device status, showcasing its potential in significantly reducing liver fat in patients with advanced liver disease through cognitive behavioral therapy.